key: cord-0849392-rgdcosba
authors: Crouwel, Femke; Waaijenberg-Warmenhoven, Petra; Buiter, Hans J C; de Boer, Nanne K
title: Recurrent COVID-19 in a patient with ulcerative colitis on vedolizumab therapy
date: 2020-12-22
journal: J Crohns Colitis
DOI: 10.1093/ecco-jcc/jjaa259
sha: 15decb78497d0d4eb89cd3398733d75bbf328bf9
doc_id: 849392
cord_uid: rgdcosba

nan

Biological therapy seems not to lead to an increased risk of severe COVID-19 outcomes in IBD patients, moreover some may even have a protective effect. 1 The influence of these medications on a possible re-infection is, however, not yet determined.

We present a case of a 28-year-old Caucasian female with a medical history of ulcerative colitis for which she is treated with 300mg vedolizumab every 8 weeks. During ongoing clinical remission, she had an unexpected elevated fecal calprotectin of 1037 ug/g on July 31, 2020. On August 5 she developed a sore throat, runny nose and fatigue and the diagnosis COVID-19 was confirmed on August 7 by a positive polymerase chain reaction on a nasopharyngeal swab. Her symptoms disappeared after 5 days and she had a negative swab on August 14. On October 10 she developed diarrhea, nausea, coughing, sneezing, headache, myalgia, anosmia and dysgeusia but her nasopharyngeal swab tested negative on October 11. Due to a worsening of symptoms she underwent a second swab on October 17 which now tested positive.

It is unclear whether this second episode is caused by prolonged viral shedding or by a reinfection, especially since serological antibody testing or viral genome sequencing was not performed. However, given the clinical course and duration between positive tests the latter seems most likely. One could speculate that an altered expression of angiotensin I converting enzym 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) in the gut of our patient due to vedolizumab or subclinical inflammation may have played a role. A c c e p t e d M a n u s c r i p t There was no writing assistance required for this study.

This manuscript has not been previously published and the manuscript is not under consideration elsewhere.

FC wrote the first draft of the manuscript. NdB, PW and HB critically revised the manuscript.

All authors approved the final version of the article, including the authorship list.

The data underlying this article are available in the article A c c e p t e d M a n u s c r i p t 

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Altered intestinal ACE2 levels are associated with inflammation, severe disease and response to anticytokine therapy in IBD

M a n u s c r i p t